Recent developments for Picard Medical include initiation of analyst coverage with a neutral recommendation, regulatory and clinical milestones for its artificial heart products, and capital raising activities.

• HC Wainwright & Co. initiated coverage of Picard Medical with a neutral recommendation on May 18, 2026 [N1].
• Philip Morris' IQOS retained FDA modified-risk authorization, indicating regulatory activity in related sectors on April 20, 2026 [N2].
• SynCardia Total Artificial Heart enabled a successful bridge to transplant at UCSF Health, demonstrating clinical application on February 12, 2026 [N3].
• Picard Medical announced plans to incorporate an extra design component into the SynCardia Total Artificial Heart design on January 6, 2026 [N4].
• The company planned to present data on its fully implantable Emperor Total Artificial Heart at the CSI Focus D-HF conference on December 5, 2025 [N5].
• SynCardia marked a milestone with first in vivo implantations of the next-generation Emperor Artificial Heart on November 20, 2025 [N6].
• Picard Medical reported a narrowing of losses in Q3 2025 [N7].
• The company reported increased losses in Q2 2025 despite higher revenues [N8].

The company has demonstrated progress in product development and clinical milestones, including enhancements to the SynCardia Total Artificial Heart and first in vivo implantations of the next-generation Emperor device. Capital raises through public offerings and convertible notes provide liquidity to support operations and debt repayment. Continued regulatory approvals and successful commercialization could support business growth and market acceptance.

Picard Medical has reported net losses in recent periods and faces liquidity constraints, with a current ratio below 1 and limited cash on hand. The company is currently non-compliant with NYSE listing standards due to low stockholders' equity and sustained losses, facing potential delisting risks. Market acceptance of its products and ability to secure additional financing remain uncertain, posing risks to ongoing operations and growth prospects.

Picard Medical's moat is centered on its proprietary total artificial heart technologies, including the SynCardia and Emperor devices, which have achieved clinical milestones such as in vivo implantations and presentations at medical conferences. The company's specialized medical device focus and regulatory clearances provide barriers to entry. However, the medical device market is competitive and capital intensive, requiring ongoing innovation and regulatory compliance to maintain competitive positioning.

• NYSE Listing Compliance Risk: The company received a notice from the NYSE American for non-compliance with listing standards due to stockholders' equity below required thresholds and net losses in multiple recent years. Failure to regain compliance by the November 2027 deadline could result in delisting, impacting liquidity and market access.
• Financial Performance and Liquidity Risk: Picard Medical has reported net losses and limited cash reserves, with a current ratio of 0.75 as of March 31, 2026. The company depends on capital raises and financing arrangements to fund operations and repay debt, which may be challenging under current market conditions.
• Product Development and Commercialization Risk: The company operates in a competitive and regulated medical device market. Success depends on continued product development, regulatory approvals, clinical adoption, and market acceptance of its total artificial heart technologies.

• Picard Medical, Inc. is a Delaware corporation headquartered in Tucson, Arizona.
• The company is listed on the NYSE American exchange under the ticker PMI.
• As of May 11, 2026, Picard Medical had 92,349,845 common shares outstanding.
• The company develops and markets total artificial heart technologies, including the SynCardia Total Artificial Heart and the next-generation Emperor Total Artificial Heart.
• Picard Medical has been involved in design enhancements to the SynCardia Total Artificial Heart, including incorporation of extra design components.
• The company has presented data on its fully implantable Emperor Total Artificial Heart at medical conferences such as CSI Focus D-HF.
• SynCardia has achieved milestones including first in vivo implantations of the next-generation Emperor Artificial Heart.
• Picard Medical reported revenue of $2.13 million for the quarter ended June 30, 2025.
• The company reported a net loss of $7.62 million for the quarter ended March 31, 2026, with basic EPS of -$0.10 for the same period.
• Diluted EPS was -$0.75 as of December 31, 2025.
• As of March 31, 2026, Picard Medical had cash and cash equivalents of $121,000 and current assets of $9.51 million, with current liabilities of $12.66 million, resulting in a current ratio of 0.75 and a cash ratio of 0.01.
• The company received a notice from the NYSE American on May 8, 2026, indicating non-compliance with continued listing standards due to stockholders' equity of approximately $3.8 million as of December 31, 2025, and net losses in three of the last four fiscal years.
• Picard Medical is preparing a plan to regain compliance with NYSE listing standards by November 8, 2027.
• The company completed a registered public offering in May 2026, raising approximately $5 million before expenses, intended for working capital and debt repayment.
• Picard Medical entered into a convertible promissory note agreement in April 2026 for $555,555.56 principal amount with a 12% one-time interest charge, maturing in nine months.
• The company has disclosed risks related to potential delisting from the NYSE American, which could impact liquidity, market quotations, analyst coverage, and financing ability.
• Recent news coverage includes initiation of analyst coverage with a neutral recommendation, product development updates, and financial results announcements.